Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs GeneDx Holdings Corp (WGS) Price & Performance

AFLAC IncorporatedTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

AFLAC Incorporated vs GeneDx Holdings Corp — how do they compare? AFLAC Incorporated trades at $120.75 (market cap $60.70B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: AFLAC Incorporated is far larger — about 24.9× GeneDx Holdings Corp's market cap, and AFLAC Incorporated pays a 2.02% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

AFLWGS
Market Cap
$60.70B$2.44B
Sector
FinancialsTechnology
52-Week High
$129.55$167.51
52-Week Low
$103.55$34.51
Enterprise Value
$70.65B$2.48B
Dividend Yield
2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

AFL trades at $120.98, down 0.79% on the day, with a P/E of 13.06 and net income margin of 26.59%. Recent earnings missed estimates for three consecutive quarters, with Q3 2026 results pending. Technical indicators show a bullish overall signal despite bearish moving averages and oscillators. The company maintains a strong dividend history, with recent payouts of $0.61 per share.

Outlook remains mixed; solid profitability and dividend growth support income investors, but earnings misses and revenue declines pose near-term risks. Analyst consensus is cautious with a hold-heavy rating and price target of $118, slightly below current levels. Key catalysts include U.S. sales momentum and Japan unit performance, while currency headwinds and medical cost inflation are concerns.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS